Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Loncastuximab Tesirine and Venetoclax for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Trial Status: closed to accrual

This phase I trial tests the safety, side effects, and best dose of a new loncastuximab tesirine and venetoclax in treating patients with non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called loncastuximab, linked to a chemotherapy drug, called tesirine. Loncastuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving loncastuximab tesirine and venetoclax may work better in treating patients with non-Hodgkin lymphoma.